Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Look at EDSA, little company , halted for efficacy

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154563
(Total Views: 638)
Posted On: 10/01/2021 11:25:57 AM
Posted By: ohm20
Re: stevo180 #106368
Quote:
Look at EDSA, little company , halted for efficacy, stock runs up 1 day and they are back in the dust again.



It was foreseeable as I said on 9/20 the day before it came back down to earth.

Quote:
Took a very quick look at the company low burn rate but also low cash on hand. Not a big problem there.

The run up was based on the press release of recovery for ECMO patients. Very small patient population and SCO was dexamethasone and IL-6 inhibitors which have shown little benefit in ECMO so easy to beat. I would put effectiveness on par with lenzilumab and I gave that a 50/50 chance of being approved.

What makes me wonder is out of 198 patients at the interim why 33 were on ECMO. The trial accepted patients that were level 3 (no oxygen) to level 6 (mechanical intubation or ECMO). With more available patients at the lower levels that's where you'd expect the preponderance of patients (as in CD12). The trial also excluded those who were on mechanical ventilation or ECMO for 5 days or longer further narrowing the potential patient pool. It looks like the deck was being stacked towards critical patients.

Of interest is that they released the interim for ECMO and critically ill but not the rest of the patient population. Critically ill mortality at interim is p = .15. Expected mortality for full phase 3 would be p = .75 still not statistically significant. That numbers weren't shown for the full patient population means the results were almost certainly worse.

With the small market cap there may be a further run up. But the FOMO based on the PR is overexuburant and overbought given the actual interim results. I would expect that realization will eventually dawn and there will be a pullback on the price. If I was in I would be monitoring the price like a hawk and sell on the start of a retraction. Better to lock down the profit on a nebulous upswing and potentially buy back in lower if you're confident of an approval.

Before I'd even hazard a guess to whether it's a long term hold I'd like to see the full data. If they are searching for an EUA they'd almost certainly have to change the protocol to ordinal scale 5, 6 only (high flow oxygen to ECMO).



(5)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us